Search
Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Search
Close this search box.

Press Releases

Explore our archive of official statements and announcements, covering financial results, important milestones, and various CSR initiatives.
Syngene reports full year and fourth quarter results
24th Apr, 2024
Syngene biologics manufacturing facility to be operational for US and European customers from mid-year
14th Mar, 2024
Syngene reports third quarter results
25th Jan, 2024
Syngene named one of India’s Best Managed Companies by Deloitte
15th Jan, 2024
Syngene International announces the winners of the 2nd edition of the Annual Science Quiz held in Bangalore and Dakshin Kannada
11th Dec, 2023
Syngene concludes the acquisition of biologics manufacturing facility from Stelis Biopharma Ltd
1st Dec, 2023
Syngene reports strong second quarter results
17th Oct, 2023
Syngene purchases land to expand operations in Genome Valley, Hyderabad
14th Sep, 2023
Q1 FY24 revenue up 26%, PAT up 26%
25th Jul, 2023
Syngene to acquire multi-model facility from Stelis Biopharma Ltd
2nd Jul, 2023

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements. To find out more, read our Privacy Policy and Cookies Policy.

To view or email, Please share your details view

To download, Please share your details